We will develop and validate a new assay system to replace existing immunocytochemicalassays for detecting occult micrometastases in bone marrow of patients with primary breast cancer.This assay would offer simplicity, low cost, and a quantitative end point. The assay is based on aninnovative… More

DESCRIPTION (Provided by applicant): BCR Diagnostics, Inc. (BCR) proposes to demonstrate the feasibility of adapting its LEXSAS (Label-free Exponential Signal-Amplification System) technology for real-time bacteriologic analysis of blood products intended for transfusion. The LEXSAS technology is… More

DESCRIPTION (provided by applicant): Bacterial contamination of blood products is currently a major problem in transfusion medicine and a leading cause of transfusion-related deaths. Platelets are particularly susceptible to contamination because they are stored at room temperature. BCR… More

DESCRIPTION (provided by applicant): BCR Diagnostics, Inc. (BCR) proposes to study the feasibility of applying its low-cost biosensor technology to detecting bacteremia in real-time (i.e., less than 5 min). The premise underlying the application is that early diagnosis of bacteremia is crucial… More

DESCRIPTION (provided by applicant): BCR Diagnostics, Inc. (BCR) has recently developed and patented a technology platform for engineering fluorogenic functionality into living Bacillus spores. Fluorogenic spores (F-spores) produced at BCR appear to be physiologically identical… More

DESCRIPTION (provided by applicant): BCR Diagnostics, Inc. (BCR) has recently developed and patented a technology platform for engineering fluorogenic functionality into living Bacillus spores. Fluorogenic spores (F-spores) produced at BCR appear to be phy siologically identical to normal spores… More